The invention relates generally to replication defective HSV-1 vectors, and, more particularly, the invention relates to replication defective HSV-1 vectors comprising an alteration (such as a gene deletion) that prevents expression of one or more infected cell polypeptide 4 (ICP4) and infected cell polypeptide 47 (ICP47) proteins, and their use to deliver one or more genes encoding transgenic proteins that stimulate immune destruction of tumors.

The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding an ichthyosis-associated polypeptide; viruses comprising the recombinant nucleic acids; compositions comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.

The present invention relates to oncolytic virus comprising: (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene.

The present disclosure relates to the treatment and/or prevention of age-related macular degeneration (AMD), including the advanced form of dry AMD referred to as Geographic Atrophy (GA). In particular, the present disclosure provides novel therapeutic antibodies that target components of the alternative pathway of the complement activation system, including complement factor H-related (CFHR) 4.

The present invention provides a reprogrammed functional fragment of a recombinant oncolytic virus, a combination, and an application thereof. The present invention further provides a group of transcription factors and a transcription factor combination which synergistically promote tumor cell transdifferentiation and reprogramming into non-tumor cells, an oncolytic virus expression method which achieves effective synergy of oncolytic therapy and reprogramming effects and can be effectively applied to limiting tumor worsening, and an application of transcription factors carried by the recombinant oncolytic virus in the preparation of a drug for treating tumor diseases.

A recombinant interleukin-27 (IL27) expressing virus is described. The recombinant IL27 expressing virus comprises an oncolytic virus comprising one or more exogenous nucleic acid sequences capable of expressing in IL27 protein or a biologically active portion thereof, the exogenous nucleic acid sequences being operably linked to an expression control sequence. Methods of treating cancer by in a subject by contacting a cancer cell of the subject with a recombinant IL27 expressing virus are also described.

The present disclosure provides methods and compositions for producing adeno-associated virus (rAAV) vectors.

Provided herein are non-natural herpes simplex virus (HSV) vectors and one or more polynucleotides encoding IL-21 or a biologically active fragment of IL-21 for use in the treatment of cancer.

Provided herein is a powder comprising a live, attenuated virus, recombinant human serum albumin (rHSA), a sugar other than lactose, a sugar alcohol, a source of phosphate, a source of chloride, wherein the composition is substantially free of lactose, gelatin, antibiotic, and free amino acids. In exemplary aspects, the powder is a lyophilizate of a liquid composition. Related liquid compositions, methods of preparing an oncolytic virus for administration and methods of treating melanoma are also provided herein.

The present invention relates to an oncolytic virus comprising: (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule-encoding gene.